Amgen (AMGN) 148.00 $AMGN
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 18.86 (-1.17), CMG: 396.93 (-11.96), AMGN: 148.00 (-4.27), GOOGL: 690.85 (-24.02), GOOG: 678.40 (-23.47), CELGZ: 1.45 (+0.01), CELG: 98.35 (-2.31)
Achromatopsia - Pipeline Review, H1 2016 Featuring Amgen & Applied Genetic Technologies Corporation - Research and Markets
BusinessWire - Thu Jun 23, 6:42AM CDT
Research and Markets has announced the addition of the "Achromatopsia - Pipeline Review, H1 2016" report to their offering.
AMGN: 148.00 (-4.27)
Amgen Sponsors QB3@953 Incubator For Life Science Startups
PR Newswire - Wed Jun 22, 5:00PM CDT
Amgen (NASDAQ:AMGN) today announced a five-year, platinum sponsorship of the QB3@953 life sciences incubator to accelerate the development of new therapies to improve human health. The shared laboratory space at QB3@953 was created to help high-potential life science and biotech startups overcome a key obstacle for many early stage organizations - access to laboratory infrastructure.
AMGN: 148.00 (-4.27)
Global Epithelial Ovarian Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: bbVie, Amgen, Sotio - Research and Markets
BusinessWire - Wed Jun 22, 10:35AM CDT
Research and Markets has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2016" drug pipelines to their offering.
AMGN: 148.00 (-4.27)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 115.00 (-2.38), MU: 13.72 (-0.33), PXD: 160.59 (+1.84), GILD: 81.77 (-1.60), EOG: 80.93 (-3.57), AMGN: 148.00 (-4.27), ABBV: 59.50 (-1.81), GOOGL: 690.85 (-24.02), CVX: 101.75 (-2.69), MSFT: 50.47 (-1.44)
Amgen Falls 1.08% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:24PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $148.50 to a high of $151.47. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $149.55 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 148.00 (-4.27)
Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
PR Newswire - Mon Jun 20, 7:25AM CDT
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
EBIO: 2.18 (-0.11), RLYP: 17.20 (-0.89), AMGN: 148.00 (-4.27), GALE: 1.96 (-0.19)
After Yesterday's Decline of 1.06%, Amgen Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jun 17, 12:16PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $149.73 to a high of $152.76. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $150.70 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 148.00 (-4.27)
Amgen Foundation Grant Funds Girl Scouts "Forever Green" Program
PRWeb - Fri Jun 17, 10:02AM CDT
Girl Scouts of California's Central Coast (GSCCC), with the support of a $15,000 grant from the Amgen Foundation, today announced the launch of this summer's "Girl Scouts Forever Green Program," which provides STEAM, (Science, Technology, Engineering, Art and Math) activities focusing on water conservation. The "Girl Scouts Forever Green Program" is a global effort encouraging girls to take action to improve the environment and protect natural resources. The program utilizes online curriculum and resources, do-it-yourself STEAM kits, and a strong network of STEAM-related volunteer and community support.
AMGN: 148.00 (-4.27)
Fitch: Clinical Outcomes Could Pave the Way For Cholesterol Drugs
BusinessWire - Tue Jun 14, 1:04PM CDT
Link to Fitch Ratings' Report: Global Pharmaceutical R&D Pipeline (Diverging Trends for Cholesterol-Lowering Drugs) https://www.fitchratings.com/creditdesk/repor..._id=882763
AMGN: 148.00 (-4.27)
Amgen's Biosimilar of AbbVie's Humira to Face FDA Panel
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 9:59AM CDT
Amgen's (AMGN) biosimilar version of AbbVie's best-selling drug, Humira, will face the FDA's Arthritis Advisory Committee.
AMGN: 148.00 (-4.27), ABBV: 59.50 (-1.81), BMY: 70.87 (-1.77), NVS: 77.65 (-3.02)
Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab
PR Newswire - Mon Jun 13, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Company's Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira® (adalimumab).
AMGN: 148.00 (-4.27)
New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
PR Newswire - Fri Jun 10, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted the benefit of continued treatment with Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) in patients with relapsed multiple myeloma. Separate sub-analyses of the Phase 3 ENDEAVOR study further confirmed efficacy and depth of response benefits of Kyprolis plus dexamethasone (Kd). These results were presented at the 21st Congress of the European Hematology Association (EHA).
AMGN: 148.00 (-4.27)
Amgen Announces Expiration And Final Results Of Senior Notes Exchange Offers
PR Newswire - Fri Jun 10, 8:00AM CDT
Amgen (NASDAQ:AMGN) announced today the expiration and final results of its previously announced seven separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers"
certain specified series of its outstanding senior notes (collectively, the "Old Notes" for new 4.563% Senior Notes due 2048 (the "New 2048 Notes" and new 4.663% Senior Notes due 2051 (the "New 2051 Notes" and, together with the New 2048 Notes, the "New Notes" , as applicable.
AMGN: 148.00 (-4.27)
Global Migraine Market Report: 2016 Edition Featuring Amgen, Teva Pharmaceuticals, Eli Lilly and Company & AstraZeneca - Research and Markets
BusinessWire - Fri Jun 10, 4:14AM CDT
Research and Markets has announced the addition of the "Global Migraine Market Report: 2016 Edition" report to their offering.
AMGN: 148.00 (-4.27), LLY: 71.76 (-2.18)
BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
PR Newswire - Fri Jun 10, 1:30AM CDT
Amgen (NASDAQ:AMGN) today announced new data from a prespecified interim analysis of the Phase 3 TOWER study, in which BLINCYTO® (blinatumomab) demonstrated an almost two-fold increase in median overall survival (OS) compared to standard of care (SOC). The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO versus SOC chemotherapy in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Results from the analysis showed that median OS was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO versus 4 months (95 percent CI: 2.9, 5.3) for SOC (stratified log-rank test p=.012; hazard ratio=0.71). As per the recommendation of an independent data monitoring committee, Amgen ended the study early for efficacy based on these results. The data will be presented during The Presidential Symposium at the 21st Congress of the European Hematology Association (EHA) in Copenhagen.
AMGN: 148.00 (-4.27)
Novartis (NVS) Announces Positive Results on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 5:22PM CDT
Novartis AG (NVS) reported positive first results from the global phase II study, 20120295 on pipeline candidate, AMG 334 (erenumab).
PFE: 33.97 (-0.62), AMGN: 148.00 (-4.27), BMY: 70.87 (-1.77), NVS: 77.65 (-3.02)
Look for Shares of Amgen to Potentially Rebound after Yesterday's 1.18% Sell Off
Comtex SmarTrend(R) - Thu Jun 09, 12:23PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.00 to a high of $158.98. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $157.54 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 148.00 (-4.27)
Watch for Amgen to Potentially Rebound After Falling 1.18% Yesterday
Comtex SmarTrend(R) - Thu Jun 09, 12:21PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.00 to a high of $158.98. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $157.54 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 148.00 (-4.27)
Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine
PR Newswire - Wed Jun 08, 3:30PM CDT
Amgen (NASDAQ:AMGN) today announced positive top-line results from the global Phase 2 study evaluating the efficacy and safety of erenumab (AMG 334) in chronic migraine prevention. The study met its primary endpoint of change in monthly migraine days. The reduction in migraine days was statistically significant for both the 70 mg and 140 mg doses.
AMGN: 148.00 (-4.27)
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 18.86 (-1.17), CMG: 396.93 (-11.96), AMGN: 148.00 (-4.27), GOOGL: 690.85 (-24.02), GOOG: 678.40 (-23.47), CELGZ: 1.45 (+0.01), CELG: 98.35 (-2.31)
Achromatopsia - Pipeline Review, H1 2016 Featuring Amgen & Applied Genetic Technologies Corporation - Research and Markets
BusinessWire - Thu Jun 23, 6:42AM CDT
Research and Markets has announced the addition of the "Achromatopsia - Pipeline Review, H1 2016" report to their offering.
AMGN: 148.00 (-4.27)
Amgen Sponsors QB3@953 Incubator For Life Science Startups
PR Newswire - Wed Jun 22, 5:00PM CDT
Amgen (NASDAQ:AMGN) today announced a five-year, platinum sponsorship of the QB3@953 life sciences incubator to accelerate the development of new therapies to improve human health. The shared laboratory space at QB3@953 was created to help high-potential life science and biotech startups overcome a key obstacle for many early stage organizations - access to laboratory infrastructure.
AMGN: 148.00 (-4.27)
Global Epithelial Ovarian Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: bbVie, Amgen, Sotio - Research and Markets
BusinessWire - Wed Jun 22, 10:35AM CDT
Research and Markets has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2016" drug pipelines to their offering.
AMGN: 148.00 (-4.27)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 115.00 (-2.38), MU: 13.72 (-0.33), PXD: 160.59 (+1.84), GILD: 81.77 (-1.60), EOG: 80.93 (-3.57), AMGN: 148.00 (-4.27), ABBV: 59.50 (-1.81), GOOGL: 690.85 (-24.02), CVX: 101.75 (-2.69), MSFT: 50.47 (-1.44)
Amgen Falls 1.08% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:24PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $148.50 to a high of $151.47. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $149.55 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 148.00 (-4.27)
Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
PR Newswire - Mon Jun 20, 7:25AM CDT
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
EBIO: 2.18 (-0.11), RLYP: 17.20 (-0.89), AMGN: 148.00 (-4.27), GALE: 1.96 (-0.19)
After Yesterday's Decline of 1.06%, Amgen Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jun 17, 12:16PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $149.73 to a high of $152.76. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $150.70 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 148.00 (-4.27)
Amgen Foundation Grant Funds Girl Scouts "Forever Green" Program
PRWeb - Fri Jun 17, 10:02AM CDT
Girl Scouts of California's Central Coast (GSCCC), with the support of a $15,000 grant from the Amgen Foundation, today announced the launch of this summer's "Girl Scouts Forever Green Program," which provides STEAM, (Science, Technology, Engineering, Art and Math) activities focusing on water conservation. The "Girl Scouts Forever Green Program" is a global effort encouraging girls to take action to improve the environment and protect natural resources. The program utilizes online curriculum and resources, do-it-yourself STEAM kits, and a strong network of STEAM-related volunteer and community support.
AMGN: 148.00 (-4.27)
Fitch: Clinical Outcomes Could Pave the Way For Cholesterol Drugs
BusinessWire - Tue Jun 14, 1:04PM CDT
Link to Fitch Ratings' Report: Global Pharmaceutical R&D Pipeline (Diverging Trends for Cholesterol-Lowering Drugs) https://www.fitchratings.com/creditdesk/repor..._id=882763
AMGN: 148.00 (-4.27)
Amgen's Biosimilar of AbbVie's Humira to Face FDA Panel
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 9:59AM CDT
Amgen's (AMGN) biosimilar version of AbbVie's best-selling drug, Humira, will face the FDA's Arthritis Advisory Committee.
AMGN: 148.00 (-4.27), ABBV: 59.50 (-1.81), BMY: 70.87 (-1.77), NVS: 77.65 (-3.02)
Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab
PR Newswire - Mon Jun 13, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Company's Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira® (adalimumab).
AMGN: 148.00 (-4.27)
New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
PR Newswire - Fri Jun 10, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted the benefit of continued treatment with Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) in patients with relapsed multiple myeloma. Separate sub-analyses of the Phase 3 ENDEAVOR study further confirmed efficacy and depth of response benefits of Kyprolis plus dexamethasone (Kd). These results were presented at the 21st Congress of the European Hematology Association (EHA).
AMGN: 148.00 (-4.27)
Amgen Announces Expiration And Final Results Of Senior Notes Exchange Offers
PR Newswire - Fri Jun 10, 8:00AM CDT
Amgen (NASDAQ:AMGN) announced today the expiration and final results of its previously announced seven separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers"
certain specified series of its outstanding senior notes (collectively, the "Old Notes" for new 4.563% Senior Notes due 2048 (the "New 2048 Notes" and new 4.663% Senior Notes due 2051 (the "New 2051 Notes" and, together with the New 2048 Notes, the "New Notes" , as applicable. AMGN: 148.00 (-4.27)
Global Migraine Market Report: 2016 Edition Featuring Amgen, Teva Pharmaceuticals, Eli Lilly and Company & AstraZeneca - Research and Markets
BusinessWire - Fri Jun 10, 4:14AM CDT
Research and Markets has announced the addition of the "Global Migraine Market Report: 2016 Edition" report to their offering.
AMGN: 148.00 (-4.27), LLY: 71.76 (-2.18)
BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
PR Newswire - Fri Jun 10, 1:30AM CDT
Amgen (NASDAQ:AMGN) today announced new data from a prespecified interim analysis of the Phase 3 TOWER study, in which BLINCYTO® (blinatumomab) demonstrated an almost two-fold increase in median overall survival (OS) compared to standard of care (SOC). The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO versus SOC chemotherapy in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Results from the analysis showed that median OS was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO versus 4 months (95 percent CI: 2.9, 5.3) for SOC (stratified log-rank test p=.012; hazard ratio=0.71). As per the recommendation of an independent data monitoring committee, Amgen ended the study early for efficacy based on these results. The data will be presented during The Presidential Symposium at the 21st Congress of the European Hematology Association (EHA) in Copenhagen.
AMGN: 148.00 (-4.27)
Novartis (NVS) Announces Positive Results on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 5:22PM CDT
Novartis AG (NVS) reported positive first results from the global phase II study, 20120295 on pipeline candidate, AMG 334 (erenumab).
PFE: 33.97 (-0.62), AMGN: 148.00 (-4.27), BMY: 70.87 (-1.77), NVS: 77.65 (-3.02)
Look for Shares of Amgen to Potentially Rebound after Yesterday's 1.18% Sell Off
Comtex SmarTrend(R) - Thu Jun 09, 12:23PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.00 to a high of $158.98. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $157.54 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 148.00 (-4.27)
Watch for Amgen to Potentially Rebound After Falling 1.18% Yesterday
Comtex SmarTrend(R) - Thu Jun 09, 12:21PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.00 to a high of $158.98. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $157.54 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 148.00 (-4.27)
Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine
PR Newswire - Wed Jun 08, 3:30PM CDT
Amgen (NASDAQ:AMGN) today announced positive top-line results from the global Phase 2 study evaluating the efficacy and safety of erenumab (AMG 334) in chronic migraine prevention. The study met its primary endpoint of change in monthly migraine days. The reduction in migraine days was statistically significant for both the 70 mg and 140 mg doses.
AMGN: 148.00 (-4.27)
